(Q33370971)

26 July 2017

Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. (English)

1 reference

26 July 2017

1 reference

Omer Faruk Kokoglu

1

1 reference

26 July 2017

Hasan Uçmak

2

1 reference

26 July 2017

Salih Hosoglu

3

1 reference

26 July 2017

Ali Cetinkaya

4

1 reference

26 July 2017

Bulent Kantarceken

5

1 reference

26 July 2017

Mehmet Akif Buyukbese

6

1 reference

26 July 2017

Ismet Onder Isik

7

1 reference

26 July 2017

1 March 2006

1 reference

Journal of Gastroenterology and Hepatology

26 July 2017

1 reference

26 July 2017

21

1 reference

26 July 2017

575-580

1 reference

26 July 2017

3

1 reference

Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Prevention and treatment of hepatitis C virus recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Hepatitis C and renal disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Hepatitis C infection and the patient with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

Understudied populations with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04008.X

10.1111/J.1440-1746.2005.04008.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference